Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A ; day:22 ; month:12 ; year:2016 ; pages:1-11
Clinical pharmacokinetics ; (22.12.2016), 1-11
- Schlagwort
-
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Urheber
-
Shah, Anita
- Beteiligte Personen und Organisationen
-
Solms, Alexander
Garmann, Dirk
Katterle, Yvonne
Avramova, Verzhiniya
Simeonov, Stanislav
Lissitchkov, Toshko
SpringerLink (Online service)
- DOI
-
10.1007/s40262-016-0492-2
- URN
-
urn:nbn:de:1111-201701208076
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:43 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shah, Anita
- Solms, Alexander
- Garmann, Dirk
- Katterle, Yvonne
- Avramova, Verzhiniya
- Simeonov, Stanislav
- Lissitchkov, Toshko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacokinetics of Human Factor IX in a dog with Severe Hemophilia B.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Investigating clinical pharmacokinetics of brivaracetam by using a pharmacokinetic modeling approach
Pharmacokinetics of Human Factor IX in a dog with Severe Hemophilia B.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Investigating clinical pharmacokinetics of brivaracetam by using a pharmacokinetic modeling approach
Pharmacokinetics of Human Factor IX in a dog with Severe Hemophilia B.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Orthopedic surgery in patients with hemophilia
Home Treatment for Children with Hemophilia
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
Optimizing the pharmacokinetics of an 211At-labeled RGD peptide with an albumin-binding moiety via the administration of an albumin-binding inhibitor
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B